key: cord-348846-mfhxac5c
authors: Coletto, Lavinia Agra; Favalli, Ennio Giulio; Caporali, Roberto
title: Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID‐19 days
date: 2020-05-02
journal: Dermatol Ther
DOI: 10.1111/dth.13415
sha: 
doc_id: 348846
cord_uid: mfhxac5c

nan

Disease flare implies systemic inflammation and immunological disruption, two recognized factors responsible for increasing susceptibility to infection in systemic polyarthritis. 3 Furthermore, an active disease entails the need of a medical reassessment, which is best to be avoided at this time, given the higher risk of contagion due to moving around and being in the hospital.

Diabetes and metabolic syndrome are acknowledged as associated with PsA and psoriasis 4 ; these comorbidities in the setting of a poorly controlled disease may worsen due to inflammation itself. In conclusion, before interrupting a chronic therapy, even if patients with PsA have an increased risk of comorbidities and serious infections compared with patients with psoriasis, 7 we suggest evaluating not only the infectious profile of immunosuppressants but also the underlying inflammatory nature of psoriatic disease itself, especially if severe and/or associated with articular involvement.

COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action

Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford)

Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK populationbased cohort study. Rheumatology (Oxford)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts